Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: An observational study

Stefan D. Anker, Abdissa Negassa, Andrew J.S. Coats, Rizwan Afzal, Philip A. Poole-Wilson, Jay N Cohn, Salim Yusuf

Research output: Contribution to journalArticle

  • 467 Citations

Abstract

Background. Weight loss in chronic heart failure is linked to impaired survival. We aimed to assess the frequency of weight loss in patients with this disease, whether the degree of weight loss predicts mortality, and whether weight loss can be prevented by angiotensin-converting-enzyme (ACE) inhibitors. Methods. We investigated weight changes in 1929 patients from the SOLVD trial who had chronic heart failure, were free of oedema at baseline, and survived for at least 4 months after trial entry. Mean follow-up was 35 months (SD 13). We analysed the effect of weight loss at cutpoints of 5%, 7·5%, 10%, 15% (a priori), and 6% (post hoc) to identify which one best predicted outcome. To validate results, we analysed data for 619 patients in the V-HeFT II trial. Findings. 817 (42%) patients in the SOLVD trial had weight loss from baseline of 5% or more. At 8 months follow-up, all cutpoints for weight loss were significantly associated with impaired survival after adjustment for age, sex, New York Heart Association class, left ventricular ejection fraction, and treatment allocation. Weight loss of 6% or more at any time during follow-up was the strongest predictor of impaired survival (adjusted hazard ratio 2·10, 95% CI 1·77-2·49; p<0·0001). Patients on the ACE inhibitor enalapril had a lower hazard of 6% or more weight loss than did those not taking the drug (adjusted reduction 19%, p=0·0054). Results from analyses of V-HeFT II data lent support to our findings. Interpretation. Weight loss occurs frequently in patients with chronic heart disease, its reversal is rare, and when present, it is independently linked to impaired survival. Weight loss of more than 6% should be used to define the presence of cachexia in patients with chronic heart failure. In chronic heart failure, treatment with an ACE inhibitor reduces the risk of weight loss.

LanguageEnglish (US)
Pages1077-1083
Number of pages7
JournalLancet
Volume361
Issue number9363
DOIs
StatePublished - Mar 29 2003

Fingerprint

Angiotensin-Converting Enzyme Inhibitors
Observational Studies
Weight Loss
Heart Failure
Therapeutics
Survival
Cachexia
Enalapril
Stroke Volume
Heart Diseases
Edema
Chronic Disease
Weights and Measures

Cite this

Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors : An observational study. / Anker, Stefan D.; Negassa, Abdissa; Coats, Andrew J.S.; Afzal, Rizwan; Poole-Wilson, Philip A.; Cohn, Jay N; Yusuf, Salim.

In: Lancet, Vol. 361, No. 9363, 29.03.2003, p. 1077-1083.

Research output: Contribution to journalArticle

Anker, Stefan D. ; Negassa, Abdissa ; Coats, Andrew J.S. ; Afzal, Rizwan ; Poole-Wilson, Philip A. ; Cohn, Jay N ; Yusuf, Salim. / Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors : An observational study. In: Lancet. 2003 ; Vol. 361, No. 9363. pp. 1077-1083.
@article{a07b2e6246a94e34a67c4d1cb79ed4ef,
title = "Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: An observational study",
abstract = "Background. Weight loss in chronic heart failure is linked to impaired survival. We aimed to assess the frequency of weight loss in patients with this disease, whether the degree of weight loss predicts mortality, and whether weight loss can be prevented by angiotensin-converting-enzyme (ACE) inhibitors. Methods. We investigated weight changes in 1929 patients from the SOLVD trial who had chronic heart failure, were free of oedema at baseline, and survived for at least 4 months after trial entry. Mean follow-up was 35 months (SD 13). We analysed the effect of weight loss at cutpoints of 5{\%}, 7·5{\%}, 10{\%}, 15{\%} (a priori), and 6{\%} (post hoc) to identify which one best predicted outcome. To validate results, we analysed data for 619 patients in the V-HeFT II trial. Findings. 817 (42{\%}) patients in the SOLVD trial had weight loss from baseline of 5{\%} or more. At 8 months follow-up, all cutpoints for weight loss were significantly associated with impaired survival after adjustment for age, sex, New York Heart Association class, left ventricular ejection fraction, and treatment allocation. Weight loss of 6{\%} or more at any time during follow-up was the strongest predictor of impaired survival (adjusted hazard ratio 2·10, 95{\%} CI 1·77-2·49; p<0·0001). Patients on the ACE inhibitor enalapril had a lower hazard of 6{\%} or more weight loss than did those not taking the drug (adjusted reduction 19{\%}, p=0·0054). Results from analyses of V-HeFT II data lent support to our findings. Interpretation. Weight loss occurs frequently in patients with chronic heart disease, its reversal is rare, and when present, it is independently linked to impaired survival. Weight loss of more than 6{\%} should be used to define the presence of cachexia in patients with chronic heart failure. In chronic heart failure, treatment with an ACE inhibitor reduces the risk of weight loss.",
author = "Anker, {Stefan D.} and Abdissa Negassa and Coats, {Andrew J.S.} and Rizwan Afzal and Poole-Wilson, {Philip A.} and Cohn, {Jay N} and Salim Yusuf",
year = "2003",
month = "3",
day = "29",
doi = "10.1016/S0140-6736(03)12892-9",
language = "English (US)",
volume = "361",
pages = "1077--1083",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier Limited",
number = "9363",

}

TY - JOUR

T1 - Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors

T2 - The Lancet

AU - Anker, Stefan D.

AU - Negassa, Abdissa

AU - Coats, Andrew J.S.

AU - Afzal, Rizwan

AU - Poole-Wilson, Philip A.

AU - Cohn, Jay N

AU - Yusuf, Salim

PY - 2003/3/29

Y1 - 2003/3/29

N2 - Background. Weight loss in chronic heart failure is linked to impaired survival. We aimed to assess the frequency of weight loss in patients with this disease, whether the degree of weight loss predicts mortality, and whether weight loss can be prevented by angiotensin-converting-enzyme (ACE) inhibitors. Methods. We investigated weight changes in 1929 patients from the SOLVD trial who had chronic heart failure, were free of oedema at baseline, and survived for at least 4 months after trial entry. Mean follow-up was 35 months (SD 13). We analysed the effect of weight loss at cutpoints of 5%, 7·5%, 10%, 15% (a priori), and 6% (post hoc) to identify which one best predicted outcome. To validate results, we analysed data for 619 patients in the V-HeFT II trial. Findings. 817 (42%) patients in the SOLVD trial had weight loss from baseline of 5% or more. At 8 months follow-up, all cutpoints for weight loss were significantly associated with impaired survival after adjustment for age, sex, New York Heart Association class, left ventricular ejection fraction, and treatment allocation. Weight loss of 6% or more at any time during follow-up was the strongest predictor of impaired survival (adjusted hazard ratio 2·10, 95% CI 1·77-2·49; p<0·0001). Patients on the ACE inhibitor enalapril had a lower hazard of 6% or more weight loss than did those not taking the drug (adjusted reduction 19%, p=0·0054). Results from analyses of V-HeFT II data lent support to our findings. Interpretation. Weight loss occurs frequently in patients with chronic heart disease, its reversal is rare, and when present, it is independently linked to impaired survival. Weight loss of more than 6% should be used to define the presence of cachexia in patients with chronic heart failure. In chronic heart failure, treatment with an ACE inhibitor reduces the risk of weight loss.

AB - Background. Weight loss in chronic heart failure is linked to impaired survival. We aimed to assess the frequency of weight loss in patients with this disease, whether the degree of weight loss predicts mortality, and whether weight loss can be prevented by angiotensin-converting-enzyme (ACE) inhibitors. Methods. We investigated weight changes in 1929 patients from the SOLVD trial who had chronic heart failure, were free of oedema at baseline, and survived for at least 4 months after trial entry. Mean follow-up was 35 months (SD 13). We analysed the effect of weight loss at cutpoints of 5%, 7·5%, 10%, 15% (a priori), and 6% (post hoc) to identify which one best predicted outcome. To validate results, we analysed data for 619 patients in the V-HeFT II trial. Findings. 817 (42%) patients in the SOLVD trial had weight loss from baseline of 5% or more. At 8 months follow-up, all cutpoints for weight loss were significantly associated with impaired survival after adjustment for age, sex, New York Heart Association class, left ventricular ejection fraction, and treatment allocation. Weight loss of 6% or more at any time during follow-up was the strongest predictor of impaired survival (adjusted hazard ratio 2·10, 95% CI 1·77-2·49; p<0·0001). Patients on the ACE inhibitor enalapril had a lower hazard of 6% or more weight loss than did those not taking the drug (adjusted reduction 19%, p=0·0054). Results from analyses of V-HeFT II data lent support to our findings. Interpretation. Weight loss occurs frequently in patients with chronic heart disease, its reversal is rare, and when present, it is independently linked to impaired survival. Weight loss of more than 6% should be used to define the presence of cachexia in patients with chronic heart failure. In chronic heart failure, treatment with an ACE inhibitor reduces the risk of weight loss.

UR - http://www.scopus.com/inward/record.url?scp=0037471843&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037471843&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(03)12892-9

DO - 10.1016/S0140-6736(03)12892-9

M3 - Article

VL - 361

SP - 1077

EP - 1083

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 9363

ER -